(CercleFinance.com) – GeNeuro rose on the stock market this Friday following the presentation of phase 2 data confirming the potential of its temelimab in multiple sclerosis.
The biopharmaceutical company announced this morning that the primary analysis of this study – presented at the ECTRIMS congress in Amsterdam – showed an ‘excellent safety and tolerance profile’ at the highest doses.
The biomarker results further confirmed the synergistic potential to treat neurodegeneration with temelimab in addition to anti-inflammatory therapy.
As already announced, MRI biomarkers have also shown a favorable impact of temelimab in the preservation of neocortical anatomy and myelin integrity.
The phase 2 study, conducted at ASC Karolinska Institutet in Stockholm, involved a cohort of 42 patients treated with temelimab versus placebo for 48 weeks.
These individuals had confirmed disability progression without relapses after prior treatment with rituximab, an anti-CD20 drug that is very potent and effective against relapses and brain lesion formation.
Listed on the Paris Stock Exchange, the title rose 6.4% on Friday after these announcements.